Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension

Phase 2 Withdrawn Akros Pharma Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH)

Timeline

Start: 2019-03
Primary completion: 2021-03
Completion: 2021-06

Outcome

Outcome not reported

Stopped: “Corporate decision, priority change”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JTT-251	Small molecule	—	Oral

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension

Summary

Timeline

Outcome

Drugs

Indications